Document Detail

Haemodynamic, neuroendocrine and metabolic correlates of circulating cytokine concentrations in congestive heart failure.
MedLine Citation:
PMID:  9347273     Owner:  NLM     Status:  MEDLINE    
OBJECTIVES: Increased activity of pro-inflammatory cytokines in the circulation has been observed in many, though not all, patients with congestive heart failure. To identify the predictors of cytokine activation in congestive heart failure, we assessed the relationship of peripheral and hepatic venous cytokines to central haemodynamics, neuroendocrine status and intermediary metabolism in patients with moderate or severe congestive heart failure. PATIENTS AND METHODS: Concentrations of tumour necrosis factor-alpha, soluble tumour necrosis factor-receptor II and interleukin 6 were measured from peripheral and hepatic venous plasma in 58 adult cardiac patients, of whom 44 had congestive heart failure, undergoing heart catheterization, echocardiography and assessment of selected neuroendocrine and metabolic characteristics. RESULTS: Peripheral venous soluble tumour necrosis factor-receptor II was directly related to NYHA class (rs = 0.46, P < 0.001) and inversely to 6-min walking distance (rs = -0.46, P < 0.001). Peripheral venous tumour necrosis factor-alpha was related to 6-min walking distance (rs = -0.37, P < 0.01), but like soluble tumour necrosis factor-receptor II, was unrelated to other haemodynamic and neuroendocrine measurements. Peripheral venous interleukin 6 correlated with NYHA class (rs = 0.66, P < 0.001) and 6-min walking distance (rs = -0.52, P < 0.001). In addition, interleukin 6 was related to right atrial pressure (rs = 0.55, P < 0.001), pulmonary artery wedge pressure (rs = 0.50, P < 0.001) and left ventricular ejection fraction (rs = -0.39, P < 0.01); in multivariate analysis, only right atrial pressure was an independent predictor of interleukin 6 concentration (P < 0.001). Comparisons between patients with and without congestive heart failure showed significantly higher hepatic venous tumour necrosis factor-alpha, soluble tumour necrosis factor-receptor II and interleukin 6 in the heart failure group; the differences in peripheral venous cytokines were less consistent. CONCLUSIONS: In cardiac patients, increased plasma tumour necrosis factor-alpha and soluble tumour necrosis factor-receptor II are associated with symptoms of heart failure and poor exercise capacity, while the most important predictor of increased interleukin 6 is elevated systemic venous pressure. Different but still unknown mechanisms may be responsible for the increased release of cytokines in congestive heart failure.
J Lommi; K Pulkki; P Koskinen; H Näveri; H Leinonen; M Härkönen; M Kupari
Related Documents :
2778723 - Effect of pulmonary venous congestion on respiratory rate in dogs.
2031403 - Skin microcirculatory responses in chronic venous insufficiency: the effect of short-te...
3575383 - Urinary anti diuretic hormone level in essential hypertension.
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  European heart journal     Volume:  18     ISSN:  0195-668X     ISO Abbreviation:  Eur. Heart J.     Publication Date:  1997 Oct 
Date Detail:
Created Date:  1997-11-24     Completed Date:  1997-11-24     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8006263     Medline TA:  Eur Heart J     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  1620-5     Citation Subset:  IM    
Division of Cardiology (Department of Medicine), Helsinki University Central Hospital, Finland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antigens, CD / blood
Body Mass Index
Cytokines / blood*
Echocardiography, Doppler, Color
Heart Catheterization
Heart Failure / blood*,  diagnosis,  physiopathology
Hemodynamics / physiology*
Immunoenzyme Techniques
Interleukin-6 / blood
Middle Aged
Multivariate Analysis
Neurosecretory Systems / physiology*
Receptors, Tumor Necrosis Factor / blood
Receptors, Tumor Necrosis Factor, Type II
Tumor Necrosis Factor-alpha / metabolism
Reg. No./Substance:
0/Antigens, CD; 0/Cytokines; 0/Interleukin-6; 0/Receptors, Tumor Necrosis Factor; 0/Receptors, Tumor Necrosis Factor, Type II; 0/Tumor Necrosis Factor-alpha

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A prognostic computer model to predict individual outcome in interventional cardiology. The INTERVEN...
Next Document:  Skeletal muscle function at low work level as a model for daily activities in patients with chronic ...